Mission Statement, Vision, & Core Values (2026) of Huapont Life Sciences Co., Ltd.

Founded in 1994, Huapont Life Sciences Co., Ltd. (002004.SZ) combines a focused dermatology and anti-tuberculosis portfolio with an integrated manufacturing footprint-operating 2 Finished Dosage Form factories and 2 API factories-and a research team where over 40% hold doctoral or master's degrees or senior professional titles; recognized as an intellectual property advanced enterprise, the company holds more than 160 invention patents and over 390 registered trademarks while pursuing its mission to "protect human health with high-quality products," a vision to become a global leader in all-natural performance materials and accessible high-quality medicine, and core values of integrity, innovation, quality, collaboration, and social responsibility that drive continuous technological development and patient-centered product solutions

Huapont Life Sciences Co., Ltd. (002004.SZ) - Intro

• Deliver innovative, safe, and accessible pharmaceutical products that address dermatological and infectious disease needs, with a focus on tuberculosis treatment and skin health.
• Use advanced manufacturing and R&D to improve patient outcomes across China and selected international markets.

• Be a trusted leader in specialty pharmaceuticals by combining scientific excellence, robust IP, and scalable manufacturing to meet evolving public health demands.
• Create sustainable long-term value for patients, healthcare partners, employees, and shareholders (002004.SZ).

• Scientific integrity - rigorous research and evidence-based development.
• Quality and compliance - end-to-end control from API to finished dosage form.
• Innovation - continuous investment in R&D and intellectual property.
• Patient-centricity - prioritizing safety, efficacy, and accessibility.
• Collaboration - cross-disciplinary teams and partnerships to accelerate therapeutic solutions.

• R&D team composition: over 40% of the R&D staff hold doctoral or master's degrees or senior professional titles.
• Patents and trademarks: more than 160 invention patents and over 390 registered trademarks, reflecting a strong IP portfolio.
• Research focus areas: dermatology therapeutics, anti-tuberculosis regimens, formulation technology and process optimization.

• Strengthen pipeline through targeted R&D and IP protection (160+ patents).
• Scale manufacturing efficiency across two FDF and two API sites to ensure supply security and cost control.
• Maintain regulatory compliance and quality systems to meet domestic and export requirements.

Huapont Life Sciences Co., Ltd. (002004.SZ) - Overview

• Protect human health with high-quality products: a commitment to safety, efficacy and regulatory compliance across pharmaceutical and topical therapy portfolios.
• Meet evolving customer application needs through continuous quality improvement and product innovation, maintaining clinical relevance.
• Prioritize technological innovation to address diverse health needs-investing in formulation science, biocompatibility and delivery systems to improve therapeutic outcomes.
• Adopt a patient-centric approach: satisfy clinical requirements, enhance patient adherence, and ensure real-world effectiveness.
• Be faithful to human health and public well-being, committing resources to accessible, responsible product availability.
• Focus as a professional dermatological service provider in China-specializing in dermatology while expanding adjacent therapeutic applications.

• To be a leading, trusted dermatology-focused pharmaceutical company in China with growing international recognition.
• To translate R&D into widely used, evidence-backed therapies that improve quality of life for dermatology patients.
• To build scalable manufacturing and quality systems that support both domestic leadership and export growth.

• Quality-first: uncompromising quality control from raw material sourcing to finished goods release.
• Innovation-driven: sustained R&D investment to innovate formulations and treatment modalities.
• Patient-first ethics: clinical effectiveness, safety, and affordability guide decision-making.
• Integrity and compliance: adherence to regulatory, ethical and ESG standards.
• Collaboration: partnerships with clinicians, hospitals and research institutes to accelerate translational outcomes.

• Increase R&D intensity to 10-12% of revenue within three years to accelerate pipeline conversion and novel topical formulations.
• Expand dermatology product portfolio via 2-3 new clinical filings per year, aimed at addressing unmet needs such as chronic inflammatory skin diseases and wound repair.
• Strengthen GMP-compliant manufacturing capacity to support export growth-targeting 15-20% annual growth in international sales channels.
• Improve patient access programs and hospital formularies to raise real-world utilization and adherence metrics.

• Stock code: 002004.SZ - tracked by domestic equity analysts for its niche dermatology positioning and steady cashflow from established products.
• Financial discipline: balancing margin preservation with R&D and capacity investments to sustain long-term growth.
• ESG & compliance: ongoing emphasis on environmental controls in manufacturing and patient-safety pharmacovigilance.

Huapont Life Sciences Co., Ltd. (002004.SZ) - Mission Statement

• Protect human health with high-quality products as the core guiding purpose.
• Become a global leader in all-natural performance materials through continual technical innovation.
• Be a respected manufacturer known for leading brand medicines and healthcare service reputation.
• Keep pace with evolving customer application needs by emphasizing quality, adaptability, and innovation.
• Expand into a global healthcare organization recognized for affordable, high-quality medicines.
• Focus on technological innovation to meet diverse and emerging health needs worldwide.

• Intensify R&D on all-natural performance materials, aiming to advance bio-based excipients and plant-derived APIs.
• Upgrade quality systems to international GMP and regulatory standards to increase global market access.
• Scale manufacturing with modular clean-room expansion to boost capacity by 25% over 3 years.
• Pursue strategic partnerships and M&A to accelerate entry into new therapeutic areas and geographies.
• Drive cost-effective innovation to deliver high-quality, affordable medicines for broader population access.

• Year-over-year revenue and profit growth rates.
• Percentage of revenue reinvested in R&D and number of pipeline candidates advanced annually.
• Regulatory approvals obtained (domestic and international) and GMP inspections passed.
• Market penetration metrics: number of export markets, new distribution partnerships, and branded product uptake.
• Quality metrics: product defect rates, recall frequency, and customer satisfaction indices.

Huapont Life Sciences Co., Ltd. (002004.SZ) Vision Statement

• Integrity - Upholding honesty, transparency, and ethical conduct across research, manufacturing, and commercial operations.
• Innovation - Pursuing scientific and technological breakthroughs to expand therapeutic options and optimize production efficiencies.
• Quality - Maintaining end-to-end quality assurance to meet and exceed international safety and regulatory standards.
• Collaboration - Building strong internal teamwork and external partnerships with universities, research institutes, and industry peers.
• Social responsibility - Investing in community health programs, environmental management, and sustainable manufacturing practices.
• Continuous reinvention - Committing to ongoing improvement of products, processes, and business models to respond to market needs.

Operationalizing these values, Huapont structures its strategy around measurable pillars that connect R&D, manufacturing excellence, and market access. The following table summarizes key operational and governance indicators the company emphasizes when reporting performance and progress to stakeholders.

To see investor-focused context and market positioning alongside transaction and ownership trends, refer to this investor profile: Exploring Huapont Life Sciences Co., Ltd. Investor Profile: Who's Buying and Why?

• Ethical governance: leadership accountability, transparent disclosures, and adherence to compliance frameworks.
• Product lifecycle excellence: from raw-material sourcing and GMP manufacturing to distribution and post-market surveillance.
• Stakeholder engagement: structured reporting to investors, regulators, customers, and local communities to align priorities and measure impact.